(VIANEWS) – The NASDAQ opens in less than two hours and Xenetic Biosciences‘s pre-market value is already 7.71% up.
Xenetic Biosciences’s last close was $3.50, 53.33% below its 52-week high of $7.50.
The last session, NASDAQ ended with Xenetic Biosciences (XBIO) dropping 1.82% to $3.50. NASDAQ slid 1.18% to $14,592.21, after four successive sessions in a row of losses, on what was an all-around down trend exchanging session.
About Xenetic Biosciences
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Earnings Per Share
As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-2.9.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -34.98%.
More news about Xenetic Biosciences (XBIO).
